Hôpital Maisonneuve Rosemont, Montréal, QC, Canada Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2018
NCT03899285
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

GMF-U Maisonneuve-Rosemont Hospital | Hôpital Maisonneuve Rosemont, Montréal, QC, Canada

Active Ingredients

Drugs in Phase 2 Trials (2)

citalopram (celexa) (1 trial)

fe203799 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 2)

Hodgkin Disease (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2